Clinical Trials

The purpose of this study is to assess the efficacy of engasertib 40 mg QD in reducing the frequency of epistaxis compared to placebo QD during 28 weeks of double-blind treatment in subjects with moderate to severe HHT.

The purpose of this study is to develop a repository of blood and tissue from patients with epistaxis and GI bleeding secondary to the conditions described above (HHT, GAVE, SBA and OGIB).

The study aims to identify predictors of brain outcomes in Hereditary Hemorrhagic Telangiectasia (HHT) patients. The study will use the modified Rankin Score (mRS). Furthermore to define a severe bleeding phenotype in HHT for clinical trial readiness. 

This study aims to develop a novel ultra-low dose chest CT technology for use in HHT patients and to determine the lowest possible radiation dose that is achievable without sacrificing the diagnostic quality.

The purpose of this study is to develop a resource (bank) of biospecimens and data collected from individuals with a vascular tumor or malformation to facilitate discovery and development of novel biomarkers for diagnosis and treatment of disease, better elucidate etiologic factors relating to vascular anomalies, and novel targeted therapeutic strategies for vascular anomalies.